MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Apr 11, 2022

Keywords

ClinConnect Summary

The MORPHEE trial is studying how a specific treatment called extracorporeal photochemotherapy (ECP) affects different types of cells in patients with conditions like cutaneous T-cell lymphoma, graft versus host disease (GVHD), and organ rejection. The goal is to understand the different ways cells can die as a result of this therapy, which could help improve future treatments for these conditions.

To be eligible for this trial, participants need to be adults who have received ECP for at least one month as part of their treatment for GVHD or organ rejection, or for cutaneous T-cell lymphoma. Unfortunately, individuals who are pregnant, those without social security coverage, or those who may have difficulty following study guidelines won't be able to participate. If you join the trial, you'll be closely monitored and might undergo various tests to help researchers learn more about how this therapy works. Your participation could play an important role in advancing treatment options for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients
• • Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma
• Exclusion Criteria:
• • Subjects with limited legal capacity.
• • Subjects judged by the investigator to be unlikely to comply with study procedures
• • Subjects with no social security coverage.
• • Pregnant women.
• • Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.